专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL294146A Anti-cmet antibody drug conjugates and methods for their use 未知
公开(公告)号：IL294146A
公开(公告)日：2022-08-01
申请号：IL29414622
申请日：2022-06-20
申请人： ABBVIE BIOTHERAPEUTICS INC , ABBVIE INC , REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
发明人： REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
IPC分类号： A61K31/517 , A61K45/06 , A61K47/68 , A61P35/00
摘要： The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

2. 发明专利

IL262869B Anti-cmet antibody drug conjugates and methods for their use 未知
公开(公告)号：IL262869B
公开(公告)日：2022-07-01
申请号：IL26286918
申请日：2018-11-07
申请人： ABBVIE BIOTHERAPEUTICS INC , ABBVIE INC , REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
发明人： REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
IPC分类号： A61K31/517 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/68 , A61P35/00
摘要： The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

3. 发明专利

IL262869D0 Anti-cmet antibody drug conjugates and methods for their use 未知
公开(公告)号：IL262869D0
公开(公告)日：2018-12-31
申请号：IL26286918
申请日：2018-11-07
申请人： ABBVIE BIOTHERAPEUTICS INC , ABBVIE INC , REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
发明人： REILLY EDWARD B , NAUMOVSKI LOUIE , ALLAN CHRISTIAN B , WANG JIEYI , ANDERSON MARK G , AFAR DANIEL E
IPC分类号： A61K20060101
摘要： The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

4. 发明申请

WO2012044783A8 METHOD OF ACHIEVING A THYMOSIN BETA 4 CONCENTRATION IN A HUMAN PATIENT 审中-公开
公开(公告)号：WO2012044783A8
公开(公告)日：2012-04-05
申请号：PCT/US2011/053907
申请日：2011-09-29
申请人： REGENERX BIOPHARMACEUTICALS, INC. , ALLAN, Christian, B. , WALTON, William
发明人： ALLAN, Christian, B. , WALTON, William
IPC分类号： A61K38/32
摘要： The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C = (A)D ⋅ t -B , wherein C is the predetermined concentration at time t, in ng/mL, D is the dosage of thymosin beta 4 administered in mg, t is the time elapsed after administration of dosage D in hours, A is about 30 to about 38, and B is about 0.5 to about 1; and administering the dosage (D) of thymosin beta 4 to the patient. Formula I may be, for example, C=(35.6)D ⋅ t -0.754 (Formula II).

5. 发明申请

WO2012044783A3 METHOD OF ACHIEVING A THYMOSIN BETA 4 CONCENTRATION IN A HUMAN PATIENT 审中-公开
公开(公告)号：WO2012044783A3
公开(公告)日：2012-04-05
申请号：PCT/US2011/053907
申请日：2011-09-29
申请人： REGENERX BIOPHARMACEUTICALS, INC. , ALLAN, Christian, B. , WALTON, William
发明人： ALLAN, Christian, B. , WALTON, William
IPC分类号： A61K38/00 , A61P13/06 , A61P21/02
摘要： The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C = (A)D ⋅ t -B , wherein C is the predetermined concentration at time t, in ng/mL, D is the dosage of thymosin beta 4 administered in mg, t is the time elapsed after administration of dosage D in hours, A is about 30 to about 38, and B is about 0.5 to about 1; and administering the dosage (D) of thymosin beta 4 to the patient. Formula I may be, for example, C=(35.6)D ⋅ t -0.754 (Formula II).

6. 发明申请

WO2009151689A9 IMPROVED BETA THYMOSIN FRAGMENTS 审中-公开
标题翻译：改进的BETA THYMOSIN碎片
公开(公告)号：WO2009151689A9
公开(公告)日：2010-05-20
申请号：PCT/US2009037060
申请日：2009-03-13
申请人： REGENERX BIOPHARMACEUTICALS , CROCKFORD DAVID , ALLAN CHRISTIAN B , SOSNE GABRIEL
发明人： CROCKFORD DAVID , ALLAN CHRISTIAN B , SOSNE GABRIEL
IPC分类号： C12P21/06
CPC分类号： C07K14/57581 , A61K38/00

7. 发明申请

WO2004066957A2 ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：抗生素alphanubeta3抗体制剂及其用途
公开(公告)号：WO2004066957A2
公开(公告)日：2004-08-12
申请号：PCT/US2004/002701
申请日：2004-01-30
申请人： MEDIMMUNE, INC. , ALLAN, Christian, B.
发明人： ALLAN, Christian, B.
IPC分类号： A61K
CPC分类号： A61K39/39591 , C07K16/2848
摘要： The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α ν β 3 , which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin α ν β 3 , which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin α ν β 3 , a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供了抗体或抗体片段的液体制剂，其免疫特异性结合整联蛋白alphanubeta3，该制剂表现出稳定性，低至不可检测的聚集水平，以及甚至在长时间内抗体或抗体片段的生物活性也很少甚至没有丧失储存期特别地，本发明提供免疫特异性结合整联蛋白氨基酸3的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常用赋形剂。此外，本发明提供了预防，治疗或改善炎性病症，自身免疫性疾病，与整合素alphanubeta3的异常表达和/或活性相关的病症，与异常骨代谢相关的疾病，与异常血管生成或癌症相关的病症的方法利用本发明的液体制剂。

8. 发明申请

WO2010141877A1 METHOD OF TREATING STEM CELLS 审中-公开
标题翻译：治疗干细胞的方法
公开(公告)号：WO2010141877A1
公开(公告)日：2010-12-09
申请号：PCT/US2010/037487
申请日：2010-06-04
申请人： CEDARS-SINAI MEDICAL CENTER , REGENERX BIOPHARMACEUTICALS, INC. , CHAKRAVARTY, Tarun , ALLAN, Christian, B.
发明人： CHAKRAVARTY, Tarun , ALLAN, Christian, B.
IPC分类号： A61K38/00 , A61K38/24
CPC分类号： C12N5/0657 , A61K35/34 , A61K38/2292 , C12N2501/998
摘要： A method of treatment for enhancing stem cells includes providing a population of stem cells in vitro and contacting the population of stem cells with a stem cell-enhancing amount of the polypeptide agent thymosin beta 4 (Tβ4).
摘要翻译：用于增强干细胞的治疗方法包括在体外提供干细胞群，并使干细胞群与干细胞增强量的多肽试剂胸腺素β4（Tβ4）接触。

9. 发明申请

WO2005117967A3 ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：抗IL-9抗体制剂及其用途
公开(公告)号：WO2005117967A3
公开(公告)日：2007-02-01
申请号：PCT/US2005012464
申请日：2005-04-12
申请人： MEDIMMUNE INC , ALLAN CHRISTIAN B
发明人： ALLAN CHRISTIAN B
IPC分类号： A61K39/395 , A61K47/02 , A61K47/18 , C07K16/06 , C07K16/24
CPC分类号： A61K39/39591 , A61K47/02 , A61K47/183 , A61K2039/505 , C07K16/065 , C07K16/244
摘要： The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.
摘要翻译：本发明提供免疫特异性结合IL-9多肽的抗体或抗体片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且抗体或抗体片段的生物活性几乎不损失或不损失，即使在长时间的存储。特别地，本发明提供免疫特异性结合IL-9多肽的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，糖，糖醇，组氨酸以外的氨基酸（优选pKa值小于 5和7以上），和/或其它常用赋形剂。此外，本发明提供了预防，治疗或改善与IL-9多肽的异常表达和/或活性相关或特征性的疾病或病症的方法，所述异常表达和/或活性与利用本发明的液体制剂，其IL-9R或其一个或多个亚单位，自身免疫性疾病，炎性疾病，增殖性疾病或感染（优选呼吸道感染）或其一种或多种症状。

10. 发明申请

WO2007002543A3 ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES 审中-公开
标题翻译：具有优化聚合和分散型材的抗体制剂
公开(公告)号：WO2007002543A3
公开(公告)日：2007-07-19
申请号：PCT/US2006024717
申请日：2006-06-23
申请人： MEDIMMUME INC , WEI ZIPING , TOUS GUILLERMO I , SCHENERMAN MARK , ALLAN CHRISTIAN B
发明人： WEI ZIPING , TOUS GUILLERMO I , SCHENERMAN MARK , ALLAN CHRISTIAN B
IPC分类号： C07K16/10
CPC分类号： A61K9/0019 , A61K9/19 , A61K2039/505 , C07K16/1027 , G01N33/56983 , G01N33/6857 , G01N2333/135
摘要： The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
摘要翻译：本发明提供了优化免疫特异性结合感兴趣的抗原的抗体制剂的生产和纯化的方法，并且适合于对受试者的肠胃外给药，该制剂由于抗体组分在长期储存中的降解和聚集降低而表现出增加的稳定性。这样的方法提供了与通过非优化方法制备的制剂相比具有多种优点的配方，包括在这种制剂的治疗，预防和诊断中使用的不太严格或更易于获得的运输/储存条件，以及较不频繁的给药或较小的剂量。本发明还提供了利用本发明制剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式